Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patients with Crohn’s disease (CD) are rare, particularly for Asian patients. We compared the key clinical outcomes (surgery, hospitalization, and corticosteroid use) of use of these two drugs in biologic-naive Korean patients with CD. Methods: Using National Health Insurance claims, we collected data on patients who were diagnosed with CD and exposed to IFX or ADA between 2010 and 2016. Results: We included 1,488 new users of biologics (1,000 IFX users and 488 ADA users). Over a median follow-up period of 2.1 years after starting biological therapy, no significant differences were found between IFX and ADA users in the risks for surgery (ADA vs IFX: adjusted hazard ratio [aHR], 1.22; 95% confidence interval [CI], 0.81 to 1.84), hospitalization (aHR, 1.02; 95% CI, 0.81 to 1.28), and corticosteroid use (aHR, 0.82; 95% CI, 0.56 to 1.19). These results were unchanged even when only patients who used biologics for over 6 months were analyzed (aHR [95% CI]: surgery, 1.31 [0.82 to 2.11]; hospitalization, 1.02 [0.80 to 1.30]; corticosteroid use, 0.80 [0.54 to 1.18]). Additionally, these results were unchanged in patients treated with biologics as monotherapy or in combination with immunomodulators. Conclusions: In this nationwide population-based study, no significant difference was found in the long-term effectiveness of IFX and ADA in the real-world setting of biologic-naive Korean patients with CD. In the absence of trials to directly compare IFX and ADA, our study indicates that the selection of one of these two biologics can be determined by patient and/or physician preference.
Abstract
Background/Aims: Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patients with Crohn’s disease (CD) are rare, particularly for Asian patients. We compared the key clinical outcomes (surgery, hospitalization, and corticosteroid use) of use of these two drugs in biologic-naive Korean patients with CD. Methods: Using National Health Insurance claims, we collected data on patients who were diagnosed with CD and exposed to IFX or ADA between 2010 and 2016. Results: We included 1,488 new users of biologics (1,000 IFX users and 488 ADA users). Over a median follow-up period of 2.1 years after starting biological therapy, no significant differences were found between IFX and ADA users in the risks for surgery (ADA vs IFX: adjusted hazard ratio [aHR], 1.22; 95% confidence interval [CI], 0.81 to 1.84), hospitalization (aHR, 1.02; 95% CI, 0.81 to 1.28), and corticosteroid use (aHR, 0.82; 95% CI, 0.56 to 1.19). These results were unchanged even when only patients who used biologics for over 6 months were analyzed (aHR [95% CI]: surgery, 1.31 [0.82 to 2.11]; hospitalization, 1.02 [0.80 to 1.30]; corticosteroid use, 0.80 [0.54 to 1.18]). Additionally, these results were unchanged in patients treated with biologics as monotherapy or in combination with immunomodulators. Conclusions: In this nationwide population-based study, no significant difference was found in the long-term effectiveness of IFX and ADA in the real-world setting of biologic-naive Korean patients with CD. In the absence of trials to directly compare IFX and ADA, our study indicates that the selection of one of these two biologics can be determined by patient and/or physician preference.
참고문헌 (29)
- 이승훈, "Immunological pathogenesis of inflammatory bowel disease", Intestinal research, 16(1), pp.26~42 (2018), 대한장연구학회
- Choon Jin Ooi, "Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia", Intestinal research, 17(3), pp.285~310 (2019), 대한장연구학회[DOI]
- Gomollon F, "3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016 : part 1 : diagnosis and medical management", J Crohns Colitis, 11, pp.3~25 (2017)
- Hanauer SB, "Maintenance infliximab for Crohn’s disease : the ACCENT I randomised trial", Lancet, 359, pp.1541~1549 (2002)
- Hanauer SB, "Human antitumor necrosis factor monoclonal antibody(adalimumab)in Crohn’s disease : the CLASSIC-I trial", Gastroenterology, 130, pp.323~333 (2006)
- Hazlewood GS, "Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease : a network meta-analysis", Gastroenterology, 148, pp.344~354 (2015)
- Stidham RW, "Systematic review with network meta-analysis : the efficacy of anti-TNF agents for the treatment of Crohn’s disease", Aliment Pharmacol Ther, 39, pp.1349~1362 (2014)
- Mao EJ, "Systematic review with meta-analysis : comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn’s disease and ulcerative colitis", Aliment Pharmacol Ther, 45, pp.3~13 (2017)
- Di Domenicantonio R, "Populationbased cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease", Clin Epidemiol, 10, pp.203~213 (2018)
- Osterman MT, "Comparative effectiveness of infliximab and adalimumab for Crohn’s disease", Clin Gastroenterol Hepatol, 12, pp.811~817 (2014)
- Ananthakrishnan AN, "Comparative effectiveness of infliximab and adalimumab in Crohn’s disease and ulcerative colitis", Inflammn Bowel Dis, 22, pp.880~885 (2016)
- Singh S, "Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn’s disease", Clin Gastroenterol Hepatol, 14, pp.1120~1129 (2016)
- Singh S, "Comparison of infliximab with adalimumab in 827 biologicnaïve patients with Crohn’s disease : a population-based Danish cohort study", Aliment Pharmacol Ther, 47, pp.596~604 (2018)
- Hsu-Heng Yen, "Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide population-based study", Intestinal research, 17(1), pp.54~62 (2019), 대한장연구학회[DOI]
- Wee Khoon Ng, "Changing epidemiological trends of inflammatory bowel disease in Asia", Intestinal research, 14(2), pp.111~119 (2016), 대한장연구학회
- Jung YS, "Incidence and clinical outcomes of inflammatory bowel disease in South Korea, 2011-2014 : a nationwide population-based study", Dig Dis Sci, 62, pp.2102~2112 (2017)
- Jung YS, "Cancer risk in the early stages of inflammatory bowel disease in Korean patients : a nationwide population-based study", J Crohns Colitis, 11, pp.954~962 (2017)
- Han M, "Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases", J Gastroenterol Hepatol, 34, pp.1166~1174 (2019)
- Bernstein CN, "Hospitalisations and surgery in Crohn’s disease", Gut, 61, pp.622~629 (2012)
- Peyrin-Biroulet L, "The natural history of adult Crohn’s disease in populationbased cohorts", Am J Gastroenterol, 105, pp.289~297 (2010)
- Yuji Maehata, "Risk of surgery in patients with stricturing type of Crohn’s disease at the initial diagnosis: a single center experience", Intestinal research, 17(3), pp.357~364 (2019), 대한장연구학회[DOI]
- Bernstein CN, "Direct medical cost of managing IBD patients : a Canadian population-based study", Inflamm Bowel Dis, 18, pp.1498~1508 (2012)
- Singh S, "Comparative efficacy of biologic therapy in biologicnaïve patients with Crohn disease : a systematic review and network meta-analysis", Mayo Clin Proc, 89, pp.1621~1635 (2014)
- Varma P, "A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease", Intern Med J, 46, pp.798~804 (2016)
- Macaluso FS, "A propensity score-matched comparison of infliximab and adalimumab in tumour necrosis factor-α inhibitor-naïve and non-naïve patients with Crohn’s disease : real-life data from the sicilian network for inflammatory bowel disease", J Crohns Colitis, 13, pp.209~217 (2019)
- Benmassaoud A, "Comparative effectiveness of infliximab versus adalimumab in patients with biologic-naïve Crohn’s disease", Dig Dis Sci, 63, pp.1302~1310 (2018)
- Narula N, "The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn’s disease", Aliment Pharmacol Ther, 44, pp.170~180 (2016)
- Sussman DA, "Comparison of medical costs among patients using adalimumab and infliximab : a retrospective study(COMPAIRS)", Inflamm Bowel Dis, 18, pp.2043~2055 (2012)
- Cheng-Chun Ji, "Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn’s disease", Intestinal research, 15(2), pp.182~186 (2017), 대한장연구학회